BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sturm L, Bettinger D, Giesler M, Boettler T, Schmidt A, Buettner N, Thimme R, Schultheiss M. Treatment with proton pump inhibitors increases the risk for development of hepatic encephalopathy after implantation of transjugular intrahepatic portosystemic shunt (TIPS). United European Gastroenterol J 2018;6:1380-90. [PMID: 30386611 DOI: 10.1177/2050640618795928] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Lewis DS, Lee T, Konanur M, Ziegler C, Hall MD, Pabon-ramos WM, Suhocki PV, Smith TP, Kim CY, Choi SS, Ronald J. Proton Pump Inhibitor Use Is Associated with an Increased Frequency of New or Worsening Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation. Journal of Vascular and Interventional Radiology 2019;30:163-9. [DOI: 10.1016/j.jvir.2018.10.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
2 Elsaid MI, Rustgi VK. Epidemiology of Hepatic Encephalopathy. Clinics in Liver Disease 2020;24:157-74. [DOI: 10.1016/j.cld.2020.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
3 Wehmeyer MH, Horvatits T, Buchholz A, Krause L, Walter S, Zapf A, Lohse AW, Kluwe J; STOPPIT-trial group. Stop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial. Trials 2022;23:302. [PMID: 35414106 DOI: 10.1186/s13063-022-06232-w] [Reference Citation Analysis]
4 Shi D, Zhou Z, Dai Y, Pan X, Cao Q. Proton Pump Inhibitor Therapy and Hepatic Encephalopathy Risk in Cirrhotic Patients: A Systematic Review with Meta-analysis. Clin Drug Investig 2019;39:847-56. [DOI: 10.1007/s40261-019-00810-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Gairing SJ, Müller L, Kloeckner R, Galle PR, Labenz C. Review article: post-TIPSS hepatic encephalopathy-current knowledge and future perspectives. Aliment Pharmacol Ther 2022. [PMID: 35181894 DOI: 10.1111/apt.16825] [Reference Citation Analysis]
6 Ma YJ, Cao ZX, Li Y, Feng SY. Proton pump inhibitor use increases hepatic encephalopathy risk: A systematic review and meta-analysis. World J Gastroenterol 2019; 25(21): 2675-2682 [PMID: 31210718 DOI: 10.3748/wjg.v25.i21.2675] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
7 Helzberg JH, Dai R, Muir AJ, Wilder J, Lee TH, Martin JG, Kim CY, Ronald J. Socioeconomic Status Is Associated with the Risk of Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation. J Vasc Interv Radiol 2021;32:950-960.e1. [PMID: 33663923 DOI: 10.1016/j.jvir.2020.11.022] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Dai R, Sag AA, Martin JG, Befera NT, Pabon-Ramos WM, Suhocki PV, Smith TP, Kim CY, Muir AJ, Ronald J. Proton pump inhibitor use is associated with increased rates of post-TIPS hepatic encephalopathy: Replication in an independent patient cohort. Clin Imaging 2021;77:187-92. [PMID: 33940357 DOI: 10.1016/j.clinimag.2021.04.034] [Reference Citation Analysis]
9 Tantai XX, Yang LB, Wei ZC, Xiao CL, Chen LR, Wang JH, Liu N. Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: A meta-analysis. World J Gastroenterol 2019; 25(21): 2683-2698 [PMID: 31210719 DOI: 10.3748/wjg.v25.i21.2683] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]